Adbry autoinjector for atopic dermatitis now available in US

Key takeaways:

• Adbry is now available in the U.S. as a 300 mg/2 mL single-dose autoinjector for adults with atopic dermatitis.
• The original prefilled syringe will still be available.

Adbry 300 mg/2 mL single-dose autoinjector is now available for the treatment of adults with moderate to severe atopic dermatitis in the U.S., LEO Pharma announced in a press release.

“We are proud to expand the administration options for Adbry and the choices available for those adults who are living with AD,” Brian Hilberdink, executive vice president and president of LEO Pharma’s North American region, said in the release. “[This] news supports our goal to help improve the standard of care for those living with skin diseases and highlights our commitment to innovation. We will continue to work tirelessly to improve the treatment options available for various skin conditions in the U.S.”

Currently indicated for the treatment of patients aged 12 years and older with moderate to severe AD that is not adequately controlled by topical prescription therapies or for those who cannot take those therapies, Adbry (tralokinumab-ldrm, LEO Pharma), a high-affinity fully human monoclonal antibody that binds and inhibits interleukin-13, was previously only available as a 150 mg/1 mL pre-filled syringe. The introduction of this new dose will now give patients the option of cutting their administration frequency in half.

For those who prefer the prefilled syringe vs. the new autoinjector, that option will continue to be available in the U.S. for both adults and pediatric patients, according to the release.